Eesti - eesti - Ravimiamet

fairmed healthcare gmbh - levodopa+karbidopa - tablett - 100mg+25mg 100tk; 100mg+25mg 20tk; 100mg+25mg 200tk

Eesti - eesti - Ravimiamet

fairmed healthcare gmbh - levodopa+karbidopa - tablett - 250mg+25mg 20tk; 250mg+25mg 120tk; 250mg+25mg 200tk; 250mg+25mg 100tk; 250mg+25mg 60tk

Eesti - eesti - Adama

adama - vees dispergeeruvad graanulid - tribenuroon-metüül - herbitsiidid

Euroopa Liit - eesti - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminohapete ainevahetus, kaasasündinud vead - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Eesti - eesti - Ravimiamet

ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 900rÜ 1tk

Eesti - eesti - Ravimiamet

ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 150rÜ 10tk; 150rÜ 1tk; 150rÜ 5tk

Eesti - eesti - Ravimiamet

ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 75rÜ 10tk; 75rÜ 5tk; 75rÜ 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - rinnanäärmed - endokriinse ravi, anti-östrogeene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pre - või perimenopausal naiste kombineeritud ravi palbociclib tuleks koos luteiniseeriva hormooni vabastav hormoon (lhrh) agonist.

Euroopa Liit - eesti - EMA (European Medicines Agency)

merck europe b.v.  - lutropiin alfa - ovulation induction; infertility, female - suguhormoonid ja genitaalsüsteemi, - luveris koos folliikuleid stimuleeriva hormooni (fsh) preparaadiga on soovitatav folliikulite arengu stimuleerimiseks raske luteiniseeriva hormooni (lh) ja fsh puudulikkusega naistel. kliinilistes uuringutes, need patsiendid olid määratletud on endogeensed seerumi lh tase.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - olaparib - munasarjade kasvajad - antineoplastilised ained - munasarja cancerlynparza on näidustatud monotherapy eest:hooldus ravi täiskasvanud patsientidel, kellel on arenenud (figo etapid iii ja iv) brca1/2-muteerunud (germline ja/või somaatilise) kõrge-klassi epiteeli munasarja -, munajuha-või esmase peritoneaaldialüüsi vähi, kes on vastuseks (täielik või osaline) pärast lõpetamist esimese-line platinum põhineva keemiaravi. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 ja 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. patsientidel peaks olema varem ravitud mõne anthracycline ja taxane aastal (neo)abiaine või metastaatilise seade välja arvatud juhul, kui patsientidele ei sobi nende ravi (vt lõik 5. patsiendid, kellel on hormooni retseptori (hr)-positiivse rinnavähi peaks ka jõudnud või pärast eelneva endokriinse ravi, või pidada sobi endokriinse ravi. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.